1
|
Kastrinos F and Stoffel EM: History, genetics, and strategies for cancer prevention in Lynch syndrome. Clin Gastroenterol Hepatol. 12:715–727. 2014.PubMed/NCBI View Article : Google Scholar
|
2
|
Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P, De La Chapelle A and Mecklin JP: Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 118:829–834. 2000.PubMed/NCBI View Article : Google Scholar
|
3
|
Vasen HF, Watson P, Mecklin JP and Lynch HT: New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 116:1453–1456. 1999.PubMed/NCBI View Article : Google Scholar
|
4
|
Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, et al: Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 96:261–268. 2004.PubMed/NCBI View Article : Google Scholar
|
5
|
Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamaa K, Prior T, Westman JA, et al: Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 26:5783–5788. 2008.PubMed/NCBI View Article : Google Scholar
|
6
|
Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, Hopper JL, Le Marchand L, Gallinger S, Newcomb PA, et al: Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 308:1555–1565. 2012.PubMed/NCBI View Article : Google Scholar
|
7
|
Di Marco M, DAndrea E, Panic N, Baccolini V, Migliara G, Marzuillo C, De Vito C, Pastorino R, Boccia S and Villari P: Which Lynch syndrome screening programs could be implemented in the ‘Real World’? A systematic review of economic evaluations. Genet Med. 20:1131–1144. 2018.PubMed/NCBI View Article : Google Scholar
|
8
|
Mvundura M, Grosse SD, Hampel H and Palomaki GE: The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 12:93–104. 2010.PubMed/NCBI View Article : Google Scholar
|
9
|
Adar T, Rodgers LH, Shannon KM, Yoshida M, Ma T, Mattia A, Lauwers GY, Iafrate AJ, Hartford NM, Oliva E and Chung DC: Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome. Cancer. 124:3145–3153. 2018.PubMed/NCBI View Article : Google Scholar
|
10
|
Dillon JL, Gonzalez JL, DeMars L, Bloch KJ and Tafe LJ: Universal screening for Lynch syndrome in endometrial cancers: Frequency of germline mutations and identification of patients with Lynch-like syndrome. Hum Pathol. 70:121–128. 2017.PubMed/NCBI View Article : Google Scholar
|
11
|
Egoavil C, Alenda C, Castillejo A, Paya A, Peiro G, Sánchez-Heras AB, Castillejo MI, Rojas E, Barberá VM, Cigüenza S, et al: Prevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers. PLoS One. 8(e79737)2013.PubMed/NCBI View Article : Google Scholar
|
12
|
Ryan NAJ, Glaire MA, Blake D, Cabrera-Dandy M, Evans DG and Crosbie EJ: The proportion of endometrial cancers associated with Lynch syndrome: A systematic review of the literature and meta-analysis. Genet Med. 21:2167–2180. 2019.PubMed/NCBI View Article : Google Scholar
|
13
|
Gupta S, Provenzale D, Llor X, Halverson AL, Grady W, Chung DC, Haraldsdottir S, Markowitz AJ, Slavin TP Jr, Hampel H, et al: NCCN Guidelines Insights: Genetic/familial high-risk assessment: Colorectal, version 2.2019. J Natl Compr Cancer Netw. 17:1032–1041. 2019.PubMed/NCBI View Article : Google Scholar
|
14
|
Crosbie EJ, Ryan NAJ, Arends MJ, Bosse T, Burn J, Cornes JM, Crawford R, Eccles D, Frayling IM, Ghaem-Maghami S, et al: The manchester international consensus group recommendations for the management of gynecological cancers in Lynch syndrome. Genet Med. 21:2390–2400. 2019.PubMed/NCBI View Article : Google Scholar
|
15
|
Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, Church JM, Dominitz JA, Johnson DA, Kaltenbach T, et al: Guidelines on genetic evaluation and management of Lynch syndrome: A consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol. 109:1159–1179. 2014.PubMed/NCBI View Article : Google Scholar
|
16
|
Rubenstein JH, Enns R, Heidelbaugh J and Barkun A: Clinical Guidelines Committee. American gastroenterological association institute guideline on the diagnosis and management of lynch syndrome. Gastroenterology. 149:777–782. 2015.PubMed/NCBI View Article : Google Scholar
|
17
|
Vangala DB, Cauchin E, Balmaña J, Wyrwicz L, van Cutsem E, Güller U, Castells A, Carneiro F, Hammel P, Ducreux M, et al: Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018. Eur J Cancer. 104:91–103. 2018.PubMed/NCBI View Article : Google Scholar
|
18
|
Brennan B, Hemmings CT, Clark I, Yip D, Fadia M and Taupin DR: Universal molecular screening does not effectively detect Lynch syndrome in clinical practice. Therap Adv Gastroenterol. 10:361–371. 2017.PubMed/NCBI View Article : Google Scholar
|
19
|
Chika N, Eguchi H, Kumamoto K, Suzuki O, Ishibashi K, Tachikawa T, Akagi K, Tamaru JI, Okazaki Y and Ishida H: Prevalence of Lynch syndrome and Lynch-like syndrome among patients with colorectal cancer in a Japanese hospital-based population. Jpn J Clin Oncol. 47:108–117. 2017.PubMed/NCBI View Article : Google Scholar
|
20
|
Jiang W, Cai MY, Li SY, Bei JX, Wang F, Hampel H, Ling YH, Frayling IM, Sinicrope FA, Rodriguez-Bigas MA, et al: Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. Int J Cancer. 144:2161–2168. 2019.PubMed/NCBI View Article : Google Scholar
|
21
|
Li D, Hoodfar E, Jiang SF, Udaltsova N, Pham NP, Jodesty Y, Armstrong MA, Hung YY, Baker RJ, Postlethwaite D, et al: Comparison of universal versus age-restricted screening of colorectal tumors for lynch syndrome using mismatch repair immunohistochemistry: A cohort study. Ann Intern Med. 171:19–26. 2019.PubMed/NCBI View Article : Google Scholar
|
22
|
Pabinger S, Ernst K, Pulverer W, Kallmeyer R, Valdes AM, Metrustry S, Katic D, Nuzzo A, Kriegner A, Vierlinger K and Weinhaeusel A: Analysis and visualization tool for targeted amplicon bisulfite sequencing on ion torrent sequencers. PLoS One. 11(e0160227)2016.PubMed/NCBI View Article : Google Scholar
|
23
|
Crockett SD and Nagtegaal ID: Terminology, molecular features, epidemiology, and management of serrated colorectal neoplasia. Gastroenterology. 157:949–966.e4. 2019.PubMed/NCBI View Article : Google Scholar
|
24
|
Shia J, Tang LH, Vakiani E, Guillem JG, Stadler ZK, Soslow RA, Katabi N, Weiser MR, Paty PB, Temple LK, et al: Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: A 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 33:1639–1645. 2009.PubMed/NCBI View Article : Google Scholar
|
25
|
Pearlman R, Markow M, Knight D, Chen W, Arnold CA, Pritchard CC, Hampel H and Frankel WL: Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency. Mod Pathol. 31:1891–1900. 2018.PubMed/NCBI View Article : Google Scholar
|
26
|
Capper D, Voigt A, Bozukova G, Ahadova A, Kickingereder P, von Deimling A, von Knebel Doeberitz M and Kloor M: BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. Int J Cancer. 133:1624–1630. 2013.PubMed/NCBI View Article : Google Scholar
|
27
|
Toon CW, Walsh MD, Chou A, Capper D, Clarkson A, Sioson L, Clarke S, Mead S, Walters RJ, Clendenning M, et al: BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome. Am J Surg Pathol. 37:1592–1602. 2013.PubMed/NCBI View Article : Google Scholar
|
28
|
Adar T, Rodgers LH, Shannon KM, Yoshida M, Ma T, Mattia A, Lauwers GY, Iafrate AJ and Chung DC: A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome. Mod Pathol. 30:440–447. 2017.PubMed/NCBI View Article : Google Scholar
|
29
|
Newton K, Jorgensen NM, Wallace AJ, Buchanan DD, Lalloo F, McMahon RF, Hill J and Evans DG: Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC). J Med Genet. 51:789–796. 2014.PubMed/NCBI View Article : Google Scholar
|
30
|
Pérez-Carbonell L, Alenda C, Payá A, Castillejo A, Barberá VM, Guillén C, Rojas E, Acame N, Gutiérrez-Aviñó FJ, Castells A, et al: Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome. J Mol Diagn. 12:498–504. 2010.PubMed/NCBI View Article : Google Scholar
|